{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:04:56Z","timestamp":1772751896091,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.ygyno.2017.04.020","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T23:45:50Z","timestamp":1493423150000},"page":"64-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers"],"prefix":"10.1016","volume":"146","author":[{"given":"Gerardo","family":"Colon-Otero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. John","family":"Weroha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan R.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Haluska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaonan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea E.","family":"Wahner-Hendrickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aminah","family":"Jatoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew S.","family":"Block","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tri A.","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew W.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Copland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.04.020_bb0005","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jama.2016.20324","article-title":"Trends and patterns of disparities in cancer mortality among US counties, 1980\u20132014","volume":"317","author":"Mokdad","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2017.04.020_bb0010","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1067\/S0002-9378(03)00579-9","article-title":"Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades","volume":"189","author":"Barnholtz-Sloan","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0015","author":"American Cancer Society"},{"key":"10.1016\/j.ygyno.2017.04.020_bb0020","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-16-1501","article-title":"Active estrogen receptor-alpha signaling in ovarian cancer models and clinical specimens","author":"Andersen","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ygyno.2009.01.012","article-title":"A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer","volume":"113","author":"Argenta","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1757-2215-7-4","article-title":"Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice","volume":"7","author":"Hirakawa","year":"2014","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.ygyno.2017.04.020_bb0035","first-page":"2233","article-title":"CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup","volume":"8","author":"Bowman","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0040","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1525-1438.2007.01075.x","article-title":"Aromatase inhibitors in ovarian cancer: is there a role?","volume":"18","author":"Li","year":"2008","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2017.04.020_bb0045","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000077436","article-title":"Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study","volume":"66","author":"Papadimitriou","year":"2004","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2017.04.020_bb0050","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ygyno.2003.08.021","article-title":"Phase II trial of anastrozole in women with asymptomatic mullerian cancer","volume":"91","author":"del Carmen","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ygyno.2017.04.020_bb0055","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1200\/jco.2005.23.16_suppl.5063","article-title":"Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancer","volume":"23","author":"Krasner","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"18_suppl","key":"10.1016\/j.ygyno.2017.04.020_bb0060","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/jco.2006.24.18_suppl.5025","article-title":"Phase II study of letrozole in estrogen receptor (ER) positive relapsed epithelial ovarian cancer (EOC)","volume":"24","author":"Gourley","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"18_suppl","key":"10.1016\/j.ygyno.2017.04.020_bb0065","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1200\/jco.2006.24.18_suppl.5026","article-title":"Phase II study of exemestane (E) in refractory ovarian cancer (ROC)","volume":"24","author":"Verma","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"18_suppl","key":"10.1016\/j.ygyno.2017.04.020_bb0070","doi-asserted-by":"crossref","first-page":"15038","DOI":"10.1200\/jco.2006.24.18_suppl.15038","article-title":"Aromatase inhibitor therapy for estrogen receptor positive ovarian cancer","volume":"24","author":"Tchekmedyian","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"18_suppl","key":"10.1016\/j.ygyno.2017.04.020_bb0075","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1200\/jco.2007.25.18_suppl.5582","article-title":"Anti-tumor activity of letrozole in patients with recurrent advanced low malignant potential or low-grade serous ovarian tumors","volume":"25","author":"Kavanagh","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0080","doi-asserted-by":"crossref","first-page":"865s","DOI":"10.1158\/1078-0432.865s.11.2","article-title":"Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer","volume":"11","author":"Osborne","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0085","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/35035131","article-title":"Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase","volume":"407","author":"Simoncini","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2017.04.020_bb0090","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0095","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2014.58.3401","article-title":"Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma","volume":"33","author":"Slomovitz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0100","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0105","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrclinonc.2015.62","article-title":"Mouse hospital and co-clinical trial project\u2014from bench to bedside","volume":"12","author":"Clohessy","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0110","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1158\/1078-0432.CCR-13-2611","article-title":"Tumorgrafts as in vivo surrogates for women with ovarian cancer","volume":"20","author":"Weroha","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.04.020_bb0120","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation for incomplete observation","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0125","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0090-8258(92)90133-4","article-title":"Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects","volume":"47","author":"Kommoss","year":"1992","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/edrv-12-1-14","article-title":"Endocrine factors in common epithelial ovarian cancer","volume":"12","author":"Rao","year":"1991","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0135","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1006\/gyno.1996.0043","article-title":"Estrogen receptor expression is a common feature of ovarian borderline tumors","volume":"60","author":"Abu-Jawdeh","year":"1996","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0140","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum","author":"Gershenson","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0145","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.18632\/oncotarget.1799","article-title":"Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K\/AKT\/mTOR pathway","volume":"5","author":"Wheler","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2017.04.020_bb0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ygyno.2011.06.022","article-title":"Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study","volume":"123","author":"Behbakht","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0155","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ygyno.2015.12.025","article-title":"Temsirolimus in women with platinum-refractory\/resistant ovarian cancer or advanced\/recurrent endometrial carcinoma. A phase II study of the AGO-study group (AGO-GYN8)","volume":"140","author":"Emons","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0160","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s10147-010-0177-z","article-title":"Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases","volume":"16","author":"Takano","year":"2011","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0165","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0170","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2017.04.020_bb0175","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N. Engl. J. Med."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817308016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817308016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T01:48:03Z","timestamp":1658972883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817308016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S0090825817308016"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.04.020","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.04.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}